{"filing":{"accession_number":"0001193125-26-236820","cik":"0001829802","ticker":"SNSE","company_name":"Sensei Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-05-22","report_date":null,"primary_document":"d900837d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526236820/d900837d8k.htm"},"events":[{"id":10556,"run_id":9259,"accession_number":"0001193125-26-236820","anchor_item_number":"8.01","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses the Board's intention to appoint Bob Holmen as chair of the Nominating and Corporate Governance Committee effective June 12, 2026, contingent on stockholder approval of Required Company Stockholder Matters at the June 10, 2026 Annual Meeting. While the filing also mentions Karen Vousden's delayed appointment request, the principal disclosed action is the appointment of Holmen to a committee chair role, making exec_appointment the most salient classification. Board reconstitution and committee leadership changes are material to investors assessing governance structure.","company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","filing_date":"2026-05-22","form":"8-K","submitted_at":null,"items":[{"id":6893,"accession_number":"0001193125-26-236820","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the Board's intention to appoint Bob Holmen as chair of the Nominating and Corporate Governance Committee effective June 12, 2026, contingent on stockholder approval of Required Company Stockholder Matters at the June 10, 2026 Annual Meeting. While the filing also mentions Karen Vousden's delayed appointment request, the principal disclosed action is the appointment of Holmen to a committee chair role, making exec_appointment the most salient classification. Board reconstitution and committee leadership changes are material to investors assessing governance structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:27:44.743542+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6893,"accession_number":"0001193125-26-236820","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the Board's intention to appoint Bob Holmen as chair of the Nominating and Corporate Governance Committee effective June 12, 2026, contingent on stockholder approval of Required Company Stockholder Matters at the June 10, 2026 Annual Meeting. While the filing also mentions Karen Vousden's delayed appointment request, the principal disclosed action is the appointment of Holmen to a committee chair role, making exec_appointment the most salient classification. Board reconstitution and committee leadership changes are material to investors assessing governance structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:27:44.743542+00:00","company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","filing_date":"2026-05-22"}]}